Action of melatonin on squamous cell carcinoma and other tumors of the oral cavity (Review)

Oncology Letters

Volumn 7, Issue 4, 2014, Pages 923-926

  Cutando, Antonio ^a   López, Antonio Valverde ^b   De Vicente, Joaquin ^b   Gimenez, Julian López ^a   Carcía, Isaac Alias ^a   De Diego, Rafael Gomez ^c  

^a UNIVERSITY OF GRANADA   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

^c UNIVERSIDAD ALFONSO X EL SABIO   (Spain)

Author keywords

Carcinoma; Melatonin; Tumors

Indexed keywords

COLLAGEN TYPE 1; ENDOTHELIN 1; EPIDERMAL GROWTH FACTOR; ESTROGEN RECEPTOR ALPHA; G PROTEIN COUPLED RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 6; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; SOMATOMEDIN C; TELOMERASE; TUMOR NECROSIS FACTOR ALPHA;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL PROLIFERATION; DNA METHYLATION; HUMAN; MOUTH CAVITY; OSSIFICATION; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TUMOR VOLUME;

EID: 84896739649     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.1813     Document Type: Article

References (57)

1. Reiter RJ: Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr Rev 12: 151-180, 1991.
2. Reiter RJ, Tan DX and Fuentes-Broto L: Melatonin: a multitasking molecule. Prog Brain Res 181: 127-151, 2010.
3. Vanëcek J: Melatonin binding sites. J Neurochem 51: 1436-1440, 1988.
4. Cajochen C, Kräuchi K and Wirz-Justice A: Role of melatonin in the regulation of human circadian rhythms and sleep. J Neuroendocrinol 15: 432-437, 2003.
5. Acuña-Castroviejo D, Reiter RJ, Menéndez-Peláez A, Pablos MI and Burgos A: Characterization of high-affinity melatonin binding sites in purified cell nuclei of rat liver. J Pineal Res 16: 100-112, 1994.
6. Jetten AM, Kurebayashi S and Ueda E: The ROR nuclear orphan receptor subfamily: critical regulators of multiple biological processes. Prog Nucleic Acid Res Mol Biol 69: 205-247, 2001.
7. Carlberg C, Hooft van Huijsduijnen R, Staple JK, DeLamarter JF and Becker-André M: RZRs, a new family of retinoid-related orphan receptors that function as both monomers and homodimers. Mol Endocrinol 8: 757-770, 1994.
8. Reiter RJ, Paredes SD, Manchester LC and Tan DX: Reducing oxidative/nitrosative stress: a newly-discovered genre for melatonin. Crit Rev Biochem Mol Biol 44: 175-200, 2009.
9. Antón-Tay F, Ramírez G, Martínez I and Benítez-King G: In vitro stimulation of protein kinase C by melatonin. Neurochem Res 23: 601-606, 1998.
10. Soto-Vega E, Meza I, Ramírez-Rodríguez G and Benitez-King G: Melatonin stimulates calmodulin phosphorylation by protein kinase C. J Pineal Res 37: 98-106, 2004.
11. Turjanski AG, Estrin DA, Rosenstein RE, McCormick JE, Martin SR, Pastore A, Biekofsky RR and Martorana V: NMR and molecular dynamics studies of the interaction of melatonin with calmodulin. Protein Sci 13: 2925-2938, 2004.
12. Macías M, Escames G, Leon J, Coto A, Sbihi Y, Osuna A and Acuña-Castroviejo D: Calreticulin-melatonin. An unexpected relationship. Eur J Biochem 270: 832-840, 2003.
13. Nosjean O, Ferro M, Coge F, Beauverger P, Henlin JM, Lefoulon F, Fauchere JL, Delagrange P, Canet E and Boutin JA: Identification of the melatonin-binding site MT3 as the quinone reductase 2. J Biol Chem 275: 31311-31317, 2000.
14. Tan DX, Manchester LC, Hardeland R, Lopez-Burillo S, Mayo JC, Sainz RM and Reiter RJ: Melatonin: a hormone, a tissue factor, an autocoid, a paracoid, and an antioxidant vitamin. J Pineal Res 34: 75-78, 2003.
15. Hardeland R, Tan DX and Reiter RJ: Kynuramines, metabolites of melatonin and other indoles: the resurrection of an almost forgotten class of biogenic amines. J Pineal Res 47: 109-126, 2009.
16. Luchetti F, Canonico B, Betti M, Arcangeletti M, Pilolli F, Piroddi M, Canesi L, Papa S and Galli F: Melatonin signaling and cell protection function. FASEB J 24: 3603-3624, 2010.
17. Wiechmann AF and Summers JA: Circadian rhythms in the eye: the physiological significance of melatonin receptors in ocular tissues. Prog Retin Eye Res 27: 137-160, 2008.
18. Scher J, Wankiewicz E, Brown GM and Fujieda H: MT(1) melatonin receptor in the human retina: expression and localization. Invest Ophthalmol Vis Sci 43: 889-897, 2002.
19. Itoh MT, Ishizuka B, Kuribayashi Y, Amemiya A and Sumi Y: Melatonin, its precursors, and synthesizing enzyme activities in the human ovary. Mol Hum Reprod 5: 402-408, 1999.
20. Tamura H, Nakamura Y, Korkmaz A, Manchester LC, Tan DX, Sugino N and Reiter RJ: Melatonin and the ovary: physiological and pathophysiological implications. Fertil Steril 92: 328-343, 2009.
21. Bubenik GA: Localization, physiological significance and possible clinical implication of gastrointestinal melatonin. Biol Signals Recept 10: 350-366, 2001.
22. Konturek SJ, Konturek PC, Brzozowska I, Pawlik M, Sliwowski Z, Cześnikiewicz-Guzik M, Kwiecień S, Brzozowski T, Bubenik GA and Pawlik WW: Localization and biological activities of melatonin in intact and diseased gastrointestinal tract (GIT). J Physiol Pharmacol 58: 381-405, 2007.
23. Carrillo-Vico A, Calvo JR, Abreu P, Lardone PJ, García-Muriño S, Reiter RJ and Guerrero JM: Evidence of melatonin synthesis by human lymphocytes and its physiological significance: possible role as intracrine, autocrine, and/or paracrine substance. FASEB J 18: 537-539, 2004.
24. Laakso ML, Porkka-Heiskanen T, Alila A, Stenberg D and Johansson G: Correlation between salivary and serum melatonin: dependence on serum melatonin levels. J Pineal Res 9: 39-50, 1990.
25. Kennaway DJ and Voultsios A: Circadian rhythm of free melatonin in human plasma. J Clin Endocrinol Metab 83: 1013-1015, 1998.
26. Nowak R, McMillen IC, Redman J and Short RV: The correlation between serum and salivary melatonin concentrations and urinary 6-hydroxymelatonin sulphate excretion rates: two non-invasive techniques for monitoring human circadian rhythmicity. Clin Endocrinol (Oxf) 27: 445-452, 1987.
27. Tan DX, Manchester LC, Reiter RJ, Plummer BF, Hardies LJ, Weintraub ST, Vijayalaxmi and Shepherd AM: A novel melatonin metabolite, cyclic 3-hydroxymelatonin: a biomarker of in vivo hydroxyl radical generation. Biochem Biophys Res Commun 253: 614-620, 1998.
28. Mediavilla MD, Sanchez-Barcelo EJ, Tan DX, Manchester L and Reiter RJ: Basic mechanisms involved in the anti-cancer effects of melatonin. Curr Med Chem 17: 4462-4481, 2010.
29. Ravindra T, Lakshmi NK and Ahuja YR: Melatonin in pathogenesis and therapy of cancer. Indian J Med Sci 60: 523-535, 2006.
30. Jung-Hynes B, Reiter RJ and Ahmad N: Sirtuins, melatonin and circadian rhythms: building a bridge between aging and cancer. J Pineal Res 48: 9-19, 2010.
31. Benítez-King G, Soto-Vega E and Ramírez-Rodriguez G: Melatonin modulates microfilament phenotypes in epithelial cells: implications for adhesion and inhibition of cancer cell migration. Histol Histopathol 24: 789-799, 2009.
32. Cos S, González A, Martínez-Campa C, Mediavilla MD, Alonso-González C and Sánchez-Barceló EJ: Estrogen-signaling pathway: a link between breast cancer and melatonin oncostatic actions. Cancer Detect Prev 30: 118-128, 2006.
33. Cos S, González A, Martínez-Campa C, Mediavilla MD, Alonso-González C and Sánchez-Barceló EJ: Melatonin as a selective estrogen enzyme modulator. Curr Cancer Drug Targets 8: 691-702, 2008.
34. Rodriguez C, Mayo JC, Sainz RM, Antolín I, Herrera F, Martín V and Reiter RJ: Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res 36: 1-9, 2004.
35. Reiter RJ, Tan DX, Osuna C and Gitto E: Actions of melatonin in the reduction of oxidative stress. A review. J Biomed Sci 7: 444-458, 2000.
36. Molis TM, Spriggs LL and Hill SM: Modulation of estrogen receptor mRNA expression by melatonin in MCF-7 human breast cancer cells. Mol Endocrinol 8: 1681-1690, 1994.
37. Rato AG, Pedrero JG, Martinez MA, del Rio B, Lazo PS and Ramos S: Melatonin blocks the activation of estrogen receptor for DNA binding. FASEB J 13: 857-868, 1999.
38. Sainz RM, Mayo JC, Rodriguez C, Tan DX, Lopez-Burillo S and Reiter RJ: Melatonin and cell death: differential actions on apoptosis in normal and cancer cells. Cell Mol Life Sci 60: 1407-1426, 2003.
39. Leon-Blanco MM, Guerrero JM, Reiter RJ, Calvo JR and Pozo D: Melatonin inhibits telomerase activity in the MCF-7 tumor cell line both in vivo and in vitro. J Pineal Res 35: 204-211, 2003.
40. Park SY, Jang WJ, Yi EY, Jang JY, Jung Y, Jeong JW and Kim YJ: Melatonin suppresses tumor angiogenesis by inhibiting HIF-1alpha stabilization under hypoxia. J Pineal Res 48: 178-184, 2010.
41. Szczepanik M: Melatonin and its influence on immune system. J Physiol Pharmacol 58 (Suppl 6): 115-124, 2007.
42. Dubocovich ML and Markowska M: Functional MT1 and MT2 melatonin receptors in mammals. Endocrine 27: 101-110, 2005.
43. Dubocovich ML, Cardinali DP, Guardiola-Lemaitre B, Hagan RM, Sugden D, Vanhoutte PM and Yocca FD (eds): The IUPHAR compendium of receptor characterization and classification. In: Melatonin Receptors. IUPHAR Media, London, pp187-193, 1998.
44. Reppert SM: Melatonin receptors: molecular biology of a new family of G protein-coupled receptors. J Biol Rhythms 12: 528-531, 1997.
45. von Gall C, Stehle JH and Weaver DR: Mammalian melatonin receptors: molecular biology and signal transduction. Cell Tissue Res 309: 151-162, 2002.
46. Ivanova EA, Bechtold DA, Dupré SM, Brennand J, Barrett P, Luckman SM and Loudon AS: Altered metabolism in the melatonin-related receptor (GPR50) knockout mouse. Am J Physiol Endocrinol Metab 294: E176-E182, 2008.
47. Sidibe A, Mullier A, Chen P, Baroncini M, Boutin JA, Delagrange P, Prevot V and Jockers R: Expression of the orphan GPR50 protein in rodent and human dorsomedial hypothalamus, tanycytes and median eminence. J Pineal Res 48: 263-269, 2010.
48. Civelli O, Saito Y, Wang Z, Nothacker HP and Reinscheid RK: Orphan GPCRs and their ligands. Pharmacol Ther 110: 525-532, 2006.
49. Levoye A, Dam J, Ayoub MA, Guillaume JL, Couturier C, Delagrange P and Jockers R: The orphan GPR50 receptor specifically inhibits MT1 melatonin receptor function through heterodimerization. EMBO J 25: 3012-3023, 2006.
50. Tan DX, Manchester LC, Terron MP, Flores LJ, Tamura H and Reiter RJ: Melatonin as a naturally occurring co-substrate of quinone reductase-2, the putative MT3 melatonin membrane receptor: hypothesis and significance. J Pineal Res 43: 317-320, 2007.
51. Boutin JA, Marcheteau E, Hennig P, Moulharat N, Berger S, Delagrange P, Bouchet JP and Ferry G: MT3/QR2 melatonin binding site does not use melatonin as a substrate or a co-substrate. J Pineal Res 45: 524-531, 2008.
52. Ha PK and Califano JA: Promoter methylation and inactivation of tumour-suppressor genes in oral squamous-cell carcinoma. Lancet Oncol 7: 77-82, 2006.
53. Nakamura E, Kozaki K, Tsuda H, Suzuki E, Pimkhaokham A, Yamamoto G, Irie T, Tachikawa T, Amagasa T, Inazawa J and Imoto I: Frequent silencing of a putative tumor suppressor gene melatonin receptor 1 A (MTNR1A) in oral squamous-cell carcinoma. Cancer Sci 99: 1390-1400, 2008.
54. Gómez-Moreno G, Guardia J, Ferrera MJ, Cutando A and Reiter RJ: Melatonin in diseases of the oral cavity. Oral Dis 16: 242-247, 2010.
55. Chaiyarit P, Ma N, Hiraku Y, Pinlaor S, Yongvanit P, Jintakanon D, Murata M, Oikawa S and Kawanishi S: Nitrative and oxidative DNA damage in oral lichen planus in relation to human oral carcinogenesis. Cancer Sci 96: 553-559, 2005.
56. Cutando A, Aneiros-Fernández J, López-Valverde A, Arias-Santiago S, Aneiros-Cachaza J and Reiter RJ: A new perspective in oral health: potential importance and actions of melatonin receptors MT1, MT2, MT3, and RZR/ROR in the oral cavity. Arch Oral Biol 56: 944-950, 2011.
57. Cutando A, Aneiros-Fernández J, Aneiros-Cachaza J and Arias-Santiago S: Melatonin and cancer: current knowledge and its application to oral cavity tumours. J Oral Pathol Med 40: 593-597, 2011.